What KAHR medical does

KAHR Bio is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, developing DSP107, a first-in-class bispecific fusion protein for the treatment of cancer. The company's lead indication is advanced metastatic microsatellite stable colorectal cancer (MSS CRC), with a secondary program in PD(L)1-experienced non-squamous cell lung carcinoma. KAHR Bio operates with a lean team of 1–10 employees across Israel and Australia, and runs clinical operations across 18 sites in Australia and the United States.

DSP107 is a T-cell engager built on a dual-mechanism architecture: it binds CD47-overexpressing cancer cells (using CD47 as a tumor-specific docking anchor, including in liver metastases where CD47 is upregulated post-chemotherapy) and simultaneously engages the 4-1BB costimulatory receptor on T cells. This converts the tumor's "don't eat me" immune evasion signal into a T-cell activation signal, while sparing healthy red blood cells (avoiding anemia seen with other CD47 agents) and avoiding the hepatotoxicity associated with systemic 4-1BB activation. Clinical evidence to date includes a 17.5-month median overall survival in heavily pretreated MSS CRC patients treated with DSP107 plus Roche's atezolizumab (versus 10.8 months for Lonsurf + Bevacizumab standard of care), a 62% disease control rate, and demonstrated efficacy in patients with liver metastases (present in 70–80% of metastatic MSS CRC patients).

KAHR Bio has no commercial products and generates no product revenue. The company is currently enrolling a Phase IIb randomized controlled trial (initiated December 2025 following FDA IND clearance) comparing DSP107 plus atezolizumab against fruquintinib in fourth-line metastatic MSS CRC, with interim data expected late 2026 and topline in H2 2027. The business model anticipates future commercialization through pharmaceutical partnerships or licensing agreements; patents on DSP107 are valid until late 2039, supplemented by biologics exclusivity, in a market opportunity exceeding $2 billion for fourth-line MSS CRC alone.

Name

KAHR medical

Legal name

KAHR Bio

Website

https://kahrbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

KAHR Bio is a clinical-stage Israeli biopharmaceutical company developing DSP107, a first-in-class bispecific fusion protein that targets CD47 and 4-1BB to treat advanced metastatic microsatellite stable colorectal cancer and non-small cell lung cancer.

Ownership category

akta.pro rank

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Drug Development and Commercialization: KAHR Bio is a clinical-stage biopharmaceutical company developing DSP107, a novel bispecific immunotherapy. Revenue will be generated through the commercialization of approved drug therapies. The company is currently conducting Phase 2 clinical trials in MSS colorectal cancer and NSCLC, with no approved products yet and no commercial revenue currently.

Distribution channels1 record

Marketing channels4 records

Core offering

KAHR Bio develops DSP107, a first-in-class bispecific fusion protein (T-cell engager) that simultaneously blocks the CD47 'don't eat me' signal on cancer cells and activates 4-1BB costimulatory signaling on T cells. The product is being advanced through clinical trials (Phase IIb in fourth-line MSS colorectal cancer combined with atezolizumab, and Phase I/II in PD(L)1-experienced NSCLC) as an investigational immunotherapy for solid tumors. The company is pre-commercial and generates no product revenue today.

Product overview

KAHR Bio is a biotech company pioneering a single core product: DSP107, a first-in-class bispecific T-cell engager. DSP107 is a fusion protein that simultaneously blocks CD47 (the 'don't eat me' signal used by cancer cells to evade innate immunity) and activates 4-1BB on T cells to trigger adaptive immune responses against tumors. The product is being developed primarily for treating metastatic microsatellite stable colorectal cancer (MSS CRC), with ongoing clinical trials in combination with atezolizumab.

Differentiator

Problem solved

Functional benefit

Products and services

• DSP107 DSP107 is a first-in-class bispecific fusion protein (T-cell engager) that converts the tumor's CD47 'don't eat me' immune evasion signal into a T-cell activation mechanism by blocking CD47 and engaging 4-1BB costimulatory signaling on T cells. It is being developed as an investigational immunotherapy for solid tumors, with ongoing clinical trials in fourth-line metastatic MSS colorectal cancer (combined with atezolizumab) and in PD(L)1-experienced non-squamous NSCLC.

Quantifiable outcome

• 17.5 months median overall survival in advanced metastatic MSS-CRC with DSP107 + atezolizumab vs 10.8 months for Lonsurf + Bevacizumab standard of care
• +3 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Roche (Genentech)coreStrategic or Co-development PartnerKAHR Bio is conducting clinical trials combining DSP107 with Roche's atezolizumab (Tecentriq), a PD-L1 checkpoint inhibitor. The Phase 1/2 trial demonstrated a median OS of 17.5 months in MSS CRC patients with the combination. The ongoing Phase IIb trial also uses DSP107 + atezolizumab vs fruquintinib as the comparator arm, indicating an active co-development/clinical collaboration relationship.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Surface Oncology: Surface Oncology (now merged with Coherus) developed immunotherapies targeting the tumor microenvironment, with overlapping immuno-oncology mechanism focus and clinical-stage profile similar to KAHR.
• Cue Biopharma: Cue Biopharma develops Immuno-STAT bispecific T-cell engagers for cancer and autoimmune disease, comparable in mechanistic approach (T-cell engagers) and indication scope to KAHR.
• Pyxis Oncology: Pyxis Oncology is a clinical-stage immuno-oncology company developing antibody-drug conjugates and immunotherapies, with comparable indication focus in solid tumors including MSS CRC-adjacent populations.
• Macrogenics: MacroGenics develops bispecific DART molecules for immuno-oncology, including 4-1BB-targeted candidates. Comparable in bispecific T-cell engagement technology class and oncology indication focus.

Direct peers

• ALX Oncology: ALX Oncology develops evorpacept, a CD47-blocking agent in oncology. It is the most direct CD47-pathway competitor to KAHR Bio's DSP107, with overlapping indication ambitions in MSS CRC and other solid tumors.
• Trillium Therapeutics: Trillium developed magrolimab (anti-CD47) for hematologic malignancies and was acquired by Pfizer. Its CD47 program provides a direct mechanistic comparison point and competitive benchmark for DSP107.
• Compugen: Compugen is an Israeli clinical-stage immuno-oncology company whose CTO Ayelet Chajut joined KAHR from. It shares KAHR's Israel-based biotech DNA and focus on computational immunology and immune checkpoint discovery.
• BioLineRx: BioLineRx is an Israeli clinical-stage oncology company led by former KAHR CEO Yaron Pereg and former KAHR CMO Adam Foley-Comer. Direct overlap in leadership and Israeli biotech ecosystem positioning.

Broad incumbents

• Aulos Bioscience: Aulos is developing next-generation IL-2 immunotherapies led by Aron Knickerbocker (also KAHR's Board Chairman). It is comparable through shared leadership and a focus on T-cell-targeted immuno-oncology.
• Roche: Roche (Genentech) is the developer of atezolizumab (Tecentriq), the PD-L1 inhibitor combined with DSP107 in KAHR's clinical trials. As a strategic partner, Roche represents both a competitive incumbent in oncology and a potential acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds14 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KAHR medical